Clinical Trial Update: Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) [Phase 3]

View source ↗

Summary

Phase 3 trial update for avelumab in non-small cell lung cancer (JAVELIN Lung 200) completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2018-12-13